#AUA14 - Poster: Impact of prior endocrine therapy on clinical benefit of abiraterone acetate in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302

ORLANDO, FL USA (UroToday.com) - Presented by Fred Saad,1 Thian Kheoh,2 Margaret K. Yu,2 Matthew R. Smith,3 Eric J. Small,4 Peter F.A. Mulders,5 Karim Fizazi,6 Dana E. Rathkopf,7 Stéphane Oudard,8 Howard I. Scher,7 Joaquim Bellmunt,9 Mary-Ellen Taplin,9 Ian D. Davis,10 Dirk Schrijvers,11 Andrew Protheroe,12 Arturo Molina,13 Thomas W. Griffin,2 Johann S. de Bono,14 and Charles J. Ryan4 at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

aua 2014 aa saad poster thumb

1University of Montréal, Montréal, QC, Canada; 2Janssen Research & Development, Los Angeles, CA; 3Harvard Medical School and Massachusetts General Hospital, Boston, MA; 4Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; 5Radboud University Medical Centre, Nijmegen, The Netherlands; 6Institut Gustave Roussy, University of Paris Sud, Villejuif, France; 7Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; 8Georges Pompidou Hospital, Paris, France; 9Dana-Farber Cancer Institute, Boston, MA; 10Monash University and Eastern Health, Victoria, Australia; 11ZNA Middelheim Oncology Clinic, Antwerp, Belgium; 12Churchill Hospital, Oxford, United Kingdom; 13Janssen Research & Development, Menlo Park, CA; 14The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, United Kingdom

Click HERE to read an exclusive report by a UroToday medical writer